Relmada Therapeutics Secures $160M Oversubscribed Private PIPE Financing
Relmada Therapeutics raised $160 million in an oversubscribed PIPE financing by selling 29.47 million common shares at $4.75 and pre-funded warrants for 4.21 million shares at $4.749. Proceeds will support working capital, general corporate purposes and advancement of its mid-stage NDV-01 and sepranolone programs.
1. Financing Structure
Relmada entered into a PIPE financing expected to generate gross proceeds of $160 million through the sale of 29.47 million common shares and pre-funded warrants for 4.21 million shares.
2. Pricing Terms
Common shares are priced at $4.75 each, while pre-funded warrants are sold at $4.749 with an exercise price of $0.001 per share.
3. Use of Proceeds
Net proceeds, alongside existing cash and investments, will fund working capital, general corporate purposes and the advancement of its mid-stage clinical candidates NDV-01 and sepranolone.
4. Closing Timeline and Conditions
The financing is scheduled to close on or about March 11, 2026, subject to customary closing conditions and includes a registration rights agreement for resale of the securities.